WuXi Diagnostics (WXDX) is establishing a next-generation integrated diagnostic enabling platform with headquarters and a CAP-accredited Independent Clinical Laboratory in Shanghai, a production facility of In Vitro Diagnostic reagent kits and instruments in Suzhou, and an R&D center at Mayo Clinic headquarters in Rochester, U.S. It is providing multidisciplinary technology solutions to improve health care practice and advance patient care. Its core product, Enabling Solution Package (ESP), is a disease-focused total solution with advanced testing panels, medical paradigm and algorithms for disease diagnosis, and insightful medical content based on real-world clinical evidence. ESPs cover four phases of disease management: screening & early diagnosis, precision diagnosis, clinical decision support, and prognosis management. WXDX dual enabling platforms for specialized testing service and medical innovation are advancing China’ s precision diagnosis and building a new ecosystem for next generation diagnostics.